Clinical Trials
6
Active:2
Completed:2
Trial Phases
3 Phases
Early Phase 1:1
Phase 1:2
Phase 2:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (40.0%)Phase 2
2 (40.0%)Early Phase 1
1 (20.0%)Effects of Anti-PD1 Adjuvant Checkpoint Blockade Immunotherapy on Atypical/Dysplastic Nevi
Recruiting
- Conditions
- Melanoma
- Interventions
- Drug: Single agent, adjuvant anti-PD1 therapy
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-03-28
- Lead Sponsor
- John Kirkwood
- Target Recruit Count
- 30
- Registration Number
- NCT06599619
- Locations
- 🇺🇸
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
Duvelisib in Combination With Nivolumab in Patients With Advanced Unresectable Melanoma
Phase 1
Active, not recruiting
- Conditions
- Unresectable Melanoma
- Interventions
- First Posted Date
- 2020-12-30
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- John Kirkwood
- Target Recruit Count
- 13
- Registration Number
- NCT04688658
- Locations
- 🇺🇸
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
Nivolumab, BMS-936558 in Combination With Relatlimab, BMS-986016 in Patients With Metastatic Melanoma Naïve to Prior Immunotherapy in the Metastatic Setting
Phase 2
Active, not recruiting
- Conditions
- Melanoma
- Interventions
- First Posted Date
- 2018-11-16
- Last Posted Date
- 2023-09-07
- Lead Sponsor
- John Kirkwood
- Target Recruit Count
- 42
- Registration Number
- NCT03743766
- Locations
- 🇺🇸
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
Safety and Efficacy Study of Vemurafenib and High-dose Interferon Alfa-2b in Melanoma
- First Posted Date
- 2013-09-17
- Last Posted Date
- 2018-04-03
- Lead Sponsor
- John Kirkwood
- Target Recruit Count
- 7
- Registration Number
- NCT01943422
- Locations
- 🇺🇸
Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
Pilot Study Evaluating Sulforaphane in Atypical Nevi-Precursor Lesions
Early Phase 1
Completed
- Conditions
- Atypical NeviMelanoma
- Interventions
- First Posted Date
- 2012-04-02
- Last Posted Date
- 2018-01-09
- Lead Sponsor
- John Kirkwood
- Target Recruit Count
- 17
- Registration Number
- NCT01568996
- Locations
- 🇺🇸
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
- Prev
- 1
- 2
- Next
News
No news found